<DOC>
	<DOCNO>NCT00568997</DOCNO>
	<brief_summary>This study examine risk systemic malignancy pediatric patient atopic dermatitis expose Elidel 1 % cream .</brief_summary>
	<brief_title>10 Year Registry Children ( Ages 2-17 Years ) With Eczema That Have Used Pimecrolimus</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>male female great equal 2 year less equal 17 year enrollment diagnosis atopic dermatitis ( confirm treat physician ) apply pimecrolimus cream 1 % 6 week past 24 week past present history systemic malignancy , skin malignancy , lymphoproliferative disease past present use oral immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Atopic dermatitis , eczema , child , pediatric patient , pimecrolimus , malignancy , registry</keyword>
</DOC>